Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

Learn how managing high blood pressure and high cholesterol keeps your heart health in check and helps prevent liver issues such as MASH.

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better manage your health.

Steatohepatitis is an advanced stage liver dysfunction associated with steatotic liver disease. In an interview with HT lifestyle, Dr. Rohit Mehtani, assistant professor, Department of Hepatology ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Amitabh Bachchan inaugurates NASH clinic at KEM Hospital, vows to campaign for awareness and eradication of liver disease.

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...